Cartesian Therapeutics (RNAC) FCF Margin (2016 - 2025)
Historic FCF Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to 3737.17%.
- Cartesian Therapeutics' FCF Margin fell 58513800.0% to 3737.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 6315.12%, marking a year-over-year decrease of 62141400.0%. This contributed to the annual value of 84.21% for FY2024, which is 1133300.0% up from last year.
- As of Q3 2025, Cartesian Therapeutics' FCF Margin stood at 3737.17%, which was down 58513800.0% from 6750.34% recorded in Q2 2025.
- Cartesian Therapeutics' 5-year FCF Margin high stood at 2114.21% for Q3 2024, and its period low was 6750.34% during Q2 2025.
- In the last 5 years, Cartesian Therapeutics' FCF Margin had a median value of 106.02% in 2021 and averaged 582.43%.
- In the last 5 years, Cartesian Therapeutics' FCF Margin skyrocketed by 22548800bps in 2024 and then tumbled by -67003300bps in 2025.
- Quarter analysis of 5 years shows Cartesian Therapeutics' FCF Margin stood at 106.02% in 2021, then soared by 32bps to 71.81% in 2022, then crashed by -293bps to 282.48% in 2023, then soared by 459bps to 1015.42% in 2024, then crashed by -468bps to 3737.17% in 2025.
- Its FCF Margin stands at 3737.17% for Q3 2025, versus 6750.34% for Q2 2025 and 2198.45% for Q1 2025.